IL161741A0 - Methods of reversing and preventingcardiovascular pathologies - Google Patents

Methods of reversing and preventingcardiovascular pathologies

Info

Publication number
IL161741A0
IL161741A0 IL16174102A IL16174102A IL161741A0 IL 161741 A0 IL161741 A0 IL 161741A0 IL 16174102 A IL16174102 A IL 16174102A IL 16174102 A IL16174102 A IL 16174102A IL 161741 A0 IL161741 A0 IL 161741A0
Authority
IL
Israel
Prior art keywords
preventingcardiovascular
pathologies
reversing
methods
preventingcardiovascular pathologies
Prior art date
Application number
IL16174102A
Other languages
English (en)
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Publication of IL161741A0 publication Critical patent/IL161741A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16174102A 2001-11-09 2002-11-12 Methods of reversing and preventingcardiovascular pathologies IL161741A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34777801P 2001-11-09 2001-11-09
PCT/US2002/037274 WO2003039352A2 (fr) 2001-11-09 2002-11-12 Methode permettant d'inverser le processus de maladies cardio-vasculaires et de prevenir ces dernieres

Publications (1)

Publication Number Publication Date
IL161741A0 true IL161741A0 (en) 2005-11-20

Family

ID=23365233

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16174102A IL161741A0 (en) 2001-11-09 2002-11-12 Methods of reversing and preventingcardiovascular pathologies
IL161741A IL161741A (en) 2001-11-09 2004-05-03 Use of probucol monoester for the preparation of medicaments for preventing or reversing cardiovascular disease characterized by decreased lumen diameter

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161741A IL161741A (en) 2001-11-09 2004-05-03 Use of probucol monoester for the preparation of medicaments for preventing or reversing cardiovascular disease characterized by decreased lumen diameter

Country Status (9)

Country Link
US (1) US20030181520A1 (fr)
EP (1) EP1451138A4 (fr)
JP (1) JP2006506314A (fr)
KR (1) KR20050044352A (fr)
CN (1) CN100482645C (fr)
AU (1) AU2002352826B2 (fr)
CA (1) CA2466081A1 (fr)
IL (2) IL161741A0 (fr)
WO (1) WO2003039352A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294736B2 (en) * 2004-04-09 2007-11-13 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
WO2006063408A1 (fr) * 2004-12-17 2006-06-22 Stocker Ronald O Préparations et méthodes pour le traitement de troubles cardio-vasculaires
US7345191B2 (en) * 2005-02-26 2008-03-18 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
EP1874725A4 (fr) * 2005-04-21 2011-04-06 Atherogenics Inc Procede de separation de derives de probucol
WO2007044726A2 (fr) * 2005-10-06 2007-04-19 Atherogenics, Inc. Procédés de réduction de l’activation plaquettaire et de traitement des accidents thrombotiques
AU2008230861A1 (en) * 2007-03-26 2008-10-02 Salutria Pharmaceuticals, Llc Methods and compositions of derivatives of probucol for the treatment of diabetes
AU2009308462B2 (en) * 2008-10-21 2015-06-11 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Animal model for evaluating vasomotor response in vivo

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4397786A (en) * 1981-11-23 1983-08-09 Merck & Co., Inc. Method of preparing statine and derivatives
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2627003B2 (ja) * 1989-01-25 1997-07-02 塩野義製薬株式会社 ジーｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
ATE294158T1 (de) * 1997-05-14 2005-05-15 Atherogenics Inc Ein monoether von probucol und methoden zur hemmung der vcam-1 expression
EP1019034A2 (fr) * 1997-07-01 2000-07-19 Atherogenics, Inc. Amelioration au moyen d'antioxydants de la therapie destinee aux etats d'hyperproliferation
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US6263342B1 (en) * 1998-04-01 2001-07-17 International Business Machines Corp. Federated searching of heterogeneous datastores using a federated datastore object
DK1140188T3 (da) * 1998-12-23 2003-09-29 Searle Llc Kombinationer af ileale galdesyretransporthæmmere og cholesterylestere tranferproteinhæmmere til cardiovaskulære indikationer
CA2356157C (fr) * 1998-12-23 2008-04-01 G.D. Searle Llc Combinaisons d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle et de derives de l'acide fibrique utilisees dans le cadre de troubles cardio-vasculaires
US6462091B1 (en) * 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6451823B1 (en) * 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity

Also Published As

Publication number Publication date
IL161741A (en) 2011-06-30
KR20050044352A (ko) 2005-05-12
EP1451138A4 (fr) 2005-06-15
AU2002352826B2 (en) 2009-05-28
EP1451138A2 (fr) 2004-09-01
JP2006506314A (ja) 2006-02-23
WO2003039352A3 (fr) 2003-10-23
US20030181520A1 (en) 2003-09-25
CN1612855A (zh) 2005-05-04
CA2466081A1 (fr) 2003-05-15
CN100482645C (zh) 2009-04-29
WO2003039352A2 (fr) 2003-05-15

Similar Documents

Publication Publication Date Title
HUP0401017A3 (en) Combination of probiotics
AU2002364528A8 (en) Bio-implant and method of making the same
EP1463742A4 (fr) Nouvelles pyrazolo-pyrimidines et pyrrolo-pyrimidines et leur utilisation
EP1408978A4 (fr) Nouvelles phenylamino-pyrimidines et leur utilisation
IL157426A0 (en) Peg-conjugates of hgf-nk4
EP1434772A4 (fr) Composes et procedes
IL154553A0 (en) Urocortin-iii and uses thereof
AU1334602A (en) Osteopontin-coated surfaces and methods of use
EP1420651A4 (fr) Conservation de produits
AU2002359694A8 (en) Compounds and methods
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
IL161741A0 (en) Methods of reversing and preventingcardiovascular pathologies
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
EP1408985A4 (fr) Nouveaux pyridopyrimidones et leurs utilisations
GB0201151D0 (en) Ground-connection structure ground-connecting member and ground-connection met d
EP1263935A4 (fr) Scytonemine et ses procedes d'utilisation
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
GB0120009D0 (en) Cause and effect diagnosis
EP1379240A4 (fr) Composes et methodes
ZA200306331B (en) Piperazinylcarbonylquinolines and isoquinolines
EP1367123A4 (fr) Neurotonine et utilisation
EP1392460A4 (fr) Hydrofluorures d'aminosilanols et leur utilisation
IL161608A0 (en) Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines
TW493722U (en) Improved structure of lampwick
EP1303281A4 (fr) Methodes de traitement